The small molecule drug developer has raised a series B round that brought its total funding to more than $100m.

Exo Therapeutics, a US-based small molecule drug developer based on research at Harvard University and Salk Institute for Biological Studies, closed a $78m series B round yesterday led by Nextech Invest.

Pharmaceutical firm Novartis took part through its Novartis Venture Fund, investing alongside 6 Dimensions Capital – the life sciences investment firm co-founded by pharmaceutical firm WuXi AppTec – as well as Samsara Biocapital, BVF Partners, Casdin Capital, Morningside, Newpath Partners and CRV.

Exo is developing a pipeline of drugs…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
email
Linked in